|
Lymphomatoid Papulosis
|
0.030 |
Biomarker
|
disease |
BEFREE |
CD30+ LPD include lymphomatoid papulosis, primary cutaneous anaplastic large-cell lymphoma, and borderline lesions.
|
29719017 |
2018 |
|
Rheumatoid Arthritis
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Of 15 patients that received biological agents after LPD development, 14 patients (93.3%) demonstrated an improved disease activity of RA and persistent remission of LPD, whereas only one patient experienced relapse of LPD during tocilizumab therapy.
|
27846761 |
2017 |
|
Lymphomatoid Papulosis
|
0.030 |
Biomarker
|
disease |
BEFREE |
More specifically the original report and subsequent authors suggest that the patients fall on the spectrum of CD30+ LPD most reminiscent of Lymphomatoid papulosis (LyP) seen in the skin.
|
29146059 |
2017 |
|
Lymphomatoid Papulosis
|
0.030 |
Biomarker
|
disease |
BEFREE |
Overlapping features of LyP and pcALCL with themselves and with other cutaneous and systemic lymphomas emphasize the importance of careful clinicopathologic correlation and staging in the diagnosis of CD30+ T-LPD.
|
27993440 |
2017 |
|
Rheumatoid Arthritis
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
The 5-year survival rate in RA-LPD (59.2%) was significantly worse than that in sporadic LPD (74.6%).
|
17117491 |
2007 |
|
Rheumatoid Arthritis
|
0.030 |
Biomarker
|
disease |
BEFREE |
Interval between the onset of RA and LPD development was significantly longer in LPD with p53 gene mutations (median 228 months) than that without mutations (133 months).
|
16988840 |
2007 |
|
Immunosuppression
|
0.030 |
Biomarker
|
disease |
BEFREE |
The clinical course of PT-LPDs is unpredictable; some patients experience regression of all lesions with a reduction in immunosuppression, whereas other patients, despite chemotherapy, radiation therapy, or surgery, rapidly die of their disease.
|
9587133 |
1998 |
|
Immunosuppression
|
0.030 |
Biomarker
|
disease |
BEFREE |
To further investigate the potential relationship of del-LMP-1 to EBV-LPDs associated with immunosuppression or immunodeficiency, we studied 39 EBV-associated lymphoproliferations (10 benign, 29 malignant) from four distinct clinical settings: posttransplant (4 malignant, 1 reactive); HIV+ (18 malignant, 2 reactive); nonimmunodeficiency malignant lymphoma (ML) (7 cases); and sporadic EBV infection with lymphoid hyperplasia (7 cases).
|
8704180 |
1996 |
|
Immunosuppression
|
0.030 |
Biomarker
|
disease |
BEFREE |
Some PT-LPDs regress after a reduction in immunosuppression, while others progress in spite of aggressive therapy.
|
7812011 |
1995 |
|
Immune thrombocytopenic purpura
|
0.020 |
Biomarker
|
disease |
BEFREE |
106 primary ITP patients (16 with newly-diagnosed ITP, 16 with persistent ITP and 74 with chronic ITP) and 39 secondary ITP patients (20 with ITP secondary to immune disorders, 7 with ITP secondary to infectious diseases and 12 with ITP secondary to lymphoproliferative disorders [LPD]) were retrospectively evaluated.
|
31840311 |
2020 |
|
Diffuse Large B-Cell Lymphoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
The patient was diagnosed as indolent T-LPD and DLBCL finally.
|
31027102 |
2019 |
|
Primary Cutaneous Anaplastic Large Cell Lymphoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
This retrospective study presents a fully clinicopathologically characterized series of pc-CD30-LPDs from an academic medical center in Brazil, including 8 lymphomatoid papulomatosis (LyP), 9 primary cutaneous anaplastic large cell lymphoma (pcALCL) and 4 borderline lesions.
|
31640798 |
2019 |
|
Adult Primary Cutaneous Anaplastic Large Cell Lymphoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
This retrospective study presents a fully clinicopathologically characterized series of pc-CD30-LPDs from an academic medical center in Brazil, including 8 lymphomatoid papulomatosis (LyP), 9 primary cutaneous anaplastic large cell lymphoma (pcALCL) and 4 borderline lesions.
|
31640798 |
2019 |
|
Inflammatory Bowel Diseases
|
0.020 |
Biomarker
|
group |
BEFREE |
Primary intestinal Epstein-Barr virus [EBV]-associated natural killer/T-cell lymphoproliferative disorder [PIEBV+ NK/T-LPD] is a rare clinical entity, which is difficult to differentiate from inflammatory bowel disease [IBD].
|
29635312 |
2018 |
|
Inflammatory Bowel Diseases
|
0.020 |
Biomarker
|
group |
BEFREE |
The best biomarker combination to differentiate UC from CD and colonic CD was BGM and VICM (AUC = 0.98, P<0.001; AUC = 0.97, P<0.001), and the best biomarker combination to differentiate IBD from IBS patients were BGM, EL-NE, and Pro-C5 (AUC = 0.8, P<0.001).
|
29028807 |
2017 |
|
Lymphoma
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Whereas the expression of CD30 in cutaneous CD30+ T-LPD stands for a favourable prognosis, its expression in other cutaneous and systemic lymphomas has a divergent impact.
|
27993440 |
2017 |
|
Immune thrombocytopenic purpura
|
0.020 |
Biomarker
|
disease |
BEFREE |
Platelet response rate was significantly lower in the LPD-ITP than in other groups.
|
28573819 |
2017 |
|
Primary Cutaneous Anaplastic Large Cell Lymphoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Overlapping features of LyP and pcALCL with themselves and with other cutaneous and systemic lymphomas emphasize the importance of careful clinicopathologic correlation and staging in the diagnosis of CD30+ T-LPD.
|
27993440 |
2017 |
|
Adult Primary Cutaneous Anaplastic Large Cell Lymphoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Overlapping features of LyP and pcALCL with themselves and with other cutaneous and systemic lymphomas emphasize the importance of careful clinicopathologic correlation and staging in the diagnosis of CD30+ T-LPD.
|
27993440 |
2017 |
|
Liver carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Repeated M-LPD TACE for HCC is feasible and safe in selected patients.
|
28551662 |
2017 |
|
Neurodegenerative Disorders
|
0.020 |
Biomarker
|
group |
BEFREE |
We show that the Drosophila bubblegum(bgm) and double bubble(dbb) genes have overlapping functions, and that the consequences of double knockout of both bubblegum and double bubble in the fly brain are profound, affecting behavior and brain morphology, and providing the best paradigm to date for an animal model of adrenoleukodystrophy (ALD), a fatal childhood neurodegenerative disease associated with the accumulation of very-long-chain fatty acids.
|
26893370 |
2016 |
|
Malignant neoplasm of breast
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
We reported previously the development of targeted LPD (liposome-polycation-DNA complex) conjugated with anti-EGFR (epidermal growth factor receptor) Fab' (TLPD-FCC) for siRNA delivery, which showed superior gene silencing activity in EGFR-overexpressing breast cancers.
|
21963149 |
2012 |
|
Liver carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Tissue distribution in vivo revealed that the accumulation of TLPD-FP75 was higher than NTLPD-FP75 in orthotopic HCC model of mice.
|
21963149 |
2012 |
|
Chronic Lymphocytic Leukemia
|
0.020 |
Biomarker
|
disease |
BEFREE |
CD160 positivity was significantly higher in CLL and HCL in terms of percentage (65.9% and 67.8%, respectively, P < .0001) and median fluorescence intensity (552 and 857, respectively, P < .0001) compared with all other B-LPD cases.
|
21715317 |
2011 |
|
Neurodegenerative Disorders
|
0.020 |
Biomarker
|
group |
BEFREE |
Its mouse/human homologs, lipidosin/bubblegum, have been suggested to participate in X-linked adrenoleukodystrophy (X-ALD), an adreno/neurodegenerative disorder with accumulation of very long chain fatty acids (VLCFA) in tissues and plasma.
|
19167491 |
2009 |